SAP155-mediated c-myc suppressor far-upstream element-binding protein-interacting repressor splicing variants are activated in colon cancer tissues

Cancer Science

Volumn 104, Issue 2, 2013, Pages 149-156

  Kajiwara, Toshiko ^a   Matsushita, Kazuyuki ^a   Itoga, Sakae ^a   Tamura, Mai ^a   Tanaka, Nobuko ^a   Tomonaga, Takeshi ^b   Matsubara, Hisahiro ^a   Shimada, Hideaki ^c   Habara, Yasuaki ^d   Matsuo, Masafumi ^d   Nomura, Fumio ^a  

^a CHIBA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^c TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FAR UPSTREAM ELEMENT BINDING PROTEIN INTERACTING REPRESSOR; MESSENGER RNA; PROTEIN VARIANT; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; CANCER DIAGNOSIS; COLORECTAL CANCER; CONTROLLED STUDY; EXON; FIBROBLAST; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; LEUKEMIA; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; TRANSCRIPTION INITIATION;

ALTERNATIVE SPLICING; ANIMALS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COLONIC NEOPLASMS; COS CELLS; EXONS; GENES, TUMOR SUPPRESSOR; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HCT116 CELLS; HELA CELLS; HUMANS; PHOSPHOPROTEINS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-MYC; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; RNA PRECURSORS; RNA SPLICING; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84873744589     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12058     Document Type: Article

References (32)

1. Traverso G, Shuber A, Levin B et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002; 346: 311-20.
2. Diehl F, Li M, Dressman D et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005; 102: 16368-73.
3. Avigan MI, Strober B, Levens D. A far upstream element stimulates c-myc expression in undifferentiated leukemia cells. J Biol Chem 1990; 265: 18538-45.
4. Duncan R, Bazar L, Michelotti G et al. A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev 1994; 8: 465-80.
5. Bazar L, Meighen D, Harris V, Duncan R, Levens D, Avigan M. Targeted melting and binding of a DNA regulatory element by a transactivator of c-myc. J Biol Chem 1995; 270: 8241-8.
6. Michelotti GA, Michelotti EF, Pullner A, Duncan RC, Eick D, Levens D. Multiple single-stranded cis elements are associated with activated chromatin of the human c-myc gene in vivo. Mol Cell Biol 1996; 16: 2656-69.
7. Liu J, He L, Collins I et al. The FBP interacting repressor targets TFIIH to inhibit activated transcription. Mol Cell 2000; 5: 331-41.
8. Liu J, Akoulitchev S, Weber A et al. Defective interplay of activators and repressors with TFIH in xeroderma pigmentosum. Cell 2001; 104: 353-63.
9. Matsushita K, Tomonaga T, Shimada H et al. An essential role of alternative splicing of c-myc suppressor FIR in carcinogenesis. Cancer Res 2006; 66: 1409-17.
10. Corsini L, Hothorn M, Stier G et al. Dimerization and protein binding specificity of the U2AF homology motif of the splicing factor Puf60. J Biol Chem 2009; 284: 630-39.
11. Matsushita K, Kajiwara T, Tamura M et al. SAP155-mediated splicing of FUSE-binding protein-interacting repressor (FIR) serves as a molecular switch for c-myc gene expression. Mol Cancer Res 2012; 10: 787-99.
12. Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 2003; 72: 291-336.
13. Sekido Y. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci 2010; 101: 1-6.
14. Sharma SV, Settleman J. Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock". Biochem Pharmacol 2010; 80: 666-73.
15. Brinkman BM. Splice variants as cancer biomarkers. Clin Biochem 2004; 37: 584-94.
16. Kaida D, Schneider-Poetsch T, Yoshida M. Splicing in oncogenesis and tumor suppression. Cancer Sci 2012; 103: 1611-6.
17. Matsushita K, Takenouchi T, Shimada H et al. Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: possible involvement of c-myc suppression by interferon-γ in situ. Cancer Sci 2006; 97: 57-63.
18. Kimura K, Nozaki N, Enomoto T, Tanaka M, Kikuchi A. Analysis of M phase-specific phosphorylation of DNA topoisomerase II. J Biol Chem 1996; 271: 21439-45.
19. Page-McCaw PS, Amonlirdviman K, Sharp PA. PUF60: a novel U2AF65-related splicing activity. RNA 1999; 5: 1548-60.
20. Kino Y, Mori D, Oma Y, Takeshita Y, Sasagawa N, Ishiura S. Muscleblind protein, MBNL1/EXP, binds specifically to CHHG repeats. Hum Mol Genet 2004; 13: 495-507.
21. Miller JW, Urbinati CR, Teng-Umnuay P et al. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J 2000; 19: 4439-48.
22. Nishida A, Kataoka N, Takeshima Y et al. Chemical treatment enhances skipping of a mutated exon in the dystrophin gene. Nat Commun 2011; 2: 308-14.
23. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561-77.
24. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-43.
25. Crichlow GV, Zhou H, Hsiao HH et al. Dimerization of FIR upon FUSE DNA binding suggests a mechanism of c-myc inhibition. EMBO J 2008; 27: 277-89.
26. Tong YK, Lo DYM. Diagnostic developments involving cell-free (circulating) nucleic acids (review). Clin Chim Acta 2006; 363: 187-96.
27. Pathak AK, Bhutani M, Kumar S et al. Circulating Cell-Free DNA in Plasma/Serum of Lung Cancer Patients as a Potential Screening and Prognostic Tool. Clin Chem 2006; 52: 1833-42.
28. Omenn GS, Yocum AK, Menon R. Alternative splice variants, a new class of protein cancer biomarker candidates: findings in pancreatic cancer and breast cancer with systems biology implications. Dis Markers 2010; 28: 241-51.
29. Matsushita K, Tomonaga T, Kajiwara T et al. c-myc suppressor FBP-interacting repressor for cancer diagnosis and therapy. Front Bios 2009; 14: 3401-8.
30. Kaida D, Motoyoshi H, Tashiro E et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol 2007; 3: 576-83.
31. Kitamura A, Matsushita K, Takiguchi Y et al. Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma. Cancer Sci 2011; 102: 1366-73.
32. Zhang J, Chen QM. Far upstream element binding protein 1: a commander of transcription, translation and beyond. Oncogene 2012; 1-10. Aug 27. doi: 10.1038/onc.2012.350.